Last updated: December 5, 2020
Sponsor: Zhejiang Cancer Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Gastric Cancer
Heartburn
Gastroesophageal Reflux Disease (Gerd)
Treatment
N/AClinical Study ID
NCT04657848
2020361093
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Preoperative endoscopy and biopsy confirmed adenocarcinoma of esophagogastricjunction, and predictively feasible of transabdominal proximal gastrectomy.
- Early gastric cancer, of preoperative staging AJCC 8th Edition cT1N0M0 and notsuitable for endoscopic resection;
- Completion of abdominal CT scan and ultrasound endoscopy
- Age:18 to 70 years ;
- Karnofsky score ≥ 70
- With good compliance and informed consent required.
Exclusion
Exclusion Criteria:
- Pregnancy, breast-feeding women.
- The existence of the peripheral nervous system disorders or significant neurologicaldisorders and a history of central nervous system disorders.
- Severity mental diseases;
- Patients with other severe complications cannot tolerate surgery: such as severe heartand lung diseases, heart function below clinical stage 2, uncontrollable hypertension,pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and / or renal insufficiency, severe hepatitis and / or function below the rank of CHILD Bgrade, and severe malnutrition, etc.
- With other malignancies which were not cured.
- Patients have already joined other clinical trials
- After signature the Clinical trial agreement, patients and their agent will quit thetrial.
Study Design
Total Participants: 100
Study Start date:
June 01, 2020
Estimated Completion Date:
June 01, 2023
Study Description
Connect with a study center
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang 310000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.